Who are AZD9833's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Fulvestrant Prefilled Syringe, Fulvestrant injection ;Dalpiciclib Isethionate, BGB-16673, HM11260C, GB491+ Fulvestrant, CKD-331.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/azd9833.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

AZD9833 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

AZD9833 (AZD9833) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Selective Estrogen Receptor Degrader (SERD). Area: Oncology.

phase 3 Selective Estrogen Receptor Degrader (SERD) Estrogen Receptor Alpha (ESR1) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

AZD9833 (AZD9833) — AstraZeneca. AZD9833 is an oral selective estrogen receptor degrader (SERD) that binds to and degrades the estrogen receptor, blocking estrogen-driven cancer cell growth.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
AZD9833 TARGET	AZD9833	AstraZeneca	phase 3	Selective Estrogen Receptor Degrader (SERD)	Estrogen Receptor Alpha (ESR1)
Fulvestrant Prefilled Syringe	Fulvestrant Prefilled Syringe	UNICANCER	phase 3	Selective estrogen receptor degrader (SERD)	Estrogen receptor alpha (ERα)
Fulvestrant injection ;Dalpiciclib Isethionate	Fulvestrant injection ;Dalpiciclib Isethionate	Shandong Suncadia Medicine Co., Ltd.	phase 3	Selective estrogen receptor degrader (SERD) + CDK4/6 inhibitor combination	Estrogen receptor (ER) and cyclin-dependent kinases 4/6 (CDK4/6)
BGB-16673	BGB-16673	BeOne Medicines	phase 3	Selective Estrogen Receptor Degrader (SERD)	Estrogen Receptor (ER)
HM11260C	HM11260C	Hanmi Pharmaceutical Company Limited	phase 3	Selective Estrogen Receptor Degrader (SERD)	Estrogen Receptor (ER)
GB491+ Fulvestrant	GB491+ Fulvestrant	Genor Biopharma Co., Ltd.	phase 3	Selective Estrogen Receptor Degrader (SERD)	Estrogen Receptor (ER)
CKD-331	CKD-331	Chong Kun Dang Pharmaceutical	phase 3	Selective Estrogen Receptor Degrader (SERD)	Estrogen Receptor Alpha (ERα)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Selective Estrogen Receptor Degrader (SERD) class)

Chong Kun Dang Pharmaceutical · 7 drugs in this class
Hanmi Pharmaceutical Company Limited · 2 drugs in this class
Dong-A ST Co., Ltd. · 1 drug in this class
Genor Biopharma Co., Ltd. · 1 drug in this class
Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
AstraZeneca · 1 drug in this class
Nanjing Chia-tai Tianqing Pharmaceutical · 1 drug in this class
BeOne Medicines · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AZD9833 — Competitive Intelligence Brief. https://druglandscape.com/ci/azd9833. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing